Over one million Canadian children are estimated to have a mental health condition, such as depression, anxiety, and attention deficit hyperactivity disorder. Many are treated with second-generation antipsychotics (SGA). In some children, SGA treatment is associated with excessive weight gain and metabolic complications including a 3-fold greater risk for type 2 diabetes. We currently have no way to identify SGA-treated children at risk for metabolic complications. The goal of our study is to determine if the fat mass and obesity-associated gene (FTO) rs9939609 variant is associated with metabolic complications in SGA-treated children. A cross-sectional population of SGA-treated (n=232) and SGA-naïve (n=378) children (≤18y) were recruited through Child and Adolescent Psychiatry at BC Children’s Hospital. Participants were genotyped, metabolic markers assessed; dietary intakes were estimated in a subset of children (n=79). The FTO rs9939609 variant genotype frequencies were not different between SGA-treated (TT 44%, TA 38%, AA 18%) and SGA-naïve (TT 42%, TA 39%, AA 19%) children. An interaction was found between SGA status and FTO genotype for fasting glucose (p=0.014). In SGA-naïve children, the A allele carriers compared to non-carriers had higher fasting glucose (4.95 vs. 4.78 mmol/L; p=0.001) in a model adjusted for age, sex, ethnicity, and zBMI. This difference was not observed in SGA-treated children. Daily energy intakes of A allele carriers were not significantly higher compared to non-carries in SGA-treated (1855 vs. 2087 kcal) and SGA-naïve (1606 vs. 1871 kcal) children. Our findings suggest that the A allele of the FTO rs9939609 variant is associated with higher fasting glucose in SGA-naïve children with mental health conditions.


A.M. Wiedeman: None. Y. Ngai: None. A.M. Henderson: None. C. Panagiotopoulos: Advisory Panel; Self; Dexcom, Inc. A.M. Devlin: None.


BC Mental Health & Substance Use Services

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.